A preliminary study on the inhibitory effect of Chunghyul-dan on stroke recurrence in patients with small vessel disease

Neurological Research

Volumn 30, Issue 6, 2008, Pages 655-658

  Cho, KiHo ^a   Noh, KiHwan ^a   Jung, WooSang ^a,b   Park, SeongUk ^a   Moon, SangKwan ^a   Park, JungMi ^a   Ko, ChangNam ^a   Kim, YoungSuk ^a   Bae, HyungSup ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Chunghyul dan; Small vessel disease; Stroke prevention

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHUNGHYUL-DAN; COPTIS RHIZOME; GARDENIAE FRUCTUS EXTRACT; HERBACEOUS AGENT; PHELLODENDRI CORTEX EXTRACT; PLANT EXTRACT; RHUBARB EXTRACT; SCUTELLARIAE RADIX;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG FORMULATION; DRUG INHIBITION; FEMALE; FOLLOW UP; FRUCTUS GARDENIAE; HERBAL MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT COMPLIANCE; PHELLODENDRI CORTEX; RECURRENT DISEASE; RISK FACTOR; STROKE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULAR LESION;

AGED; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECURRENCE; STROKE; VASCULAR DISEASES;

EID: 47749152950     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X305382     Document Type: Article

References (21)

1. Kim YS, Jung EA, Shin JE, et al. Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull 2002; 25: 1442-1445
2. Cho KH, Jung WS, Park SU, et al. Daio-Orengedokudo works as a cell-proliferating compound in endothelial cells. Can J Physiol Pharm 2004; 82: 380-386
3. Cho KH, Kim YS, Bae HS, et al. Inhibitory Effect of Chunghyul-dan in prostaglandin E2 and nitric oxide biosynthesis of lipopolysac-charide-induced RAW 264.7 Cells. Biol Pharm Bull 2004; 27: 1810-1813
4. Yun SP, Kim LD, Lee SH, et al. Antihypertensive effect Chunghyuldan on stage I hypertensive patients with stroke. Korean J Orent Int Med 2004; 25: 195-201
5. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637-676
6. Hayakawa J, Noda N, Yamada S, et al. Studies on physical chemical quality evaluation of crude drugs preparations. III. Analysis of gardenia fruits and its preparations. Yakugadu Zasshi 1986; 105: 996-1000
7. Burn J, Dennis M, Bamford J, et al. Long-term risk of recurrence stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25: 333-337
8. Petty GW, Brown RD, Jr, Whisnant JP, et al. Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50: 208-216
9. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community. The Northern Manhattan Stroke Study. Neurology 1994; 44: 626-634
10. Dominick JH, Martin MB. Prevention of ischaemic stroke -antiplatelets. Br Med Bull 2000; 56: 510-525
11. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054
12. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991; 338: 1345-1349
13. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
15. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry 1996; 60: 197-199
16. European Stroke Prevention Study. ESPS Group. Stroke 1990; 21: 1122-1130
17. Grent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220
18. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-507
19. Kim YS, Jung EA, Jang JC, et al. Anti-hyperlipidemic effect of Daehwang-hwangryeonhaedok-tang on hyperlipidemia. Korean J Pharmacogn 2001; 32: 145-152
20. Cho KH, Kang HS, Jung WS, et al. Efficacy and safety of Chunghyul-dan (Qingxie-dan) in patients with hypercholesterolemia. Am J Chin Med 2004; 33: 241-248
21. Cho KH, Jung WS, Park SU, et al. Clinical assessment on the safety of Chunghyul-dan (Qingxie-dan). J Korean Orient Med 2003; 24: 45-50